Genmab Signs Agreement with DSM Biologics to Produce Clinical and Commercial Supply of HuMax-CD4

03-Jun-2004

Copenhagen, Denmark: Genmab A/S announced it has signed an agreement with DSM Biologics to produce a commercial supply of HuMax-CD4, Genmab's antibody for the treatment of T-cell lymphoma. DSM will manufacture c-GMP batches of HuMax-CD4 for clinical trials and subsequent commercial supply. The material will be produced in DSM's facility in Groningen, the Netherlands.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances